A carregar...
Time‐Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL
Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic leukemia, according to new findings from an investigator‐initiated phase II study.
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330921/ https://ncbi.nlm.nih.gov/pubmed/32589307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0558 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|